A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

✍ Scribed by Hong, D. S.; Kurzrock, R.; Naing, A.; Wheler, J. J.; Falchook, G. S.; Schiffman, J. S.; Faulkner, N.; Pilat, M. J.; O’Brien, J.; LoRusso, P.

• Book ID: 121600844
• Publisher: Springer US
• Year: 2013
• Tongue: English
• Weight: 365 KB
• Volume: 32
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/s10637-013-0046-5